Christophe Corpechot

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 131 publications

Letter: Therapeutic Targeting of PPARs in PBC-Additional Considerations.

Letter: Therapeutic Targeting of PPARs in PBC-Additional Considerations.

Journal: Alimentary pharmacology & therapeutics

Published: April 22, 2026

Hepatic and Cardiovascular Outcomes in Primary Biliary Cholangitis With Metabolic-Dysfunction Associated Steatotic Liver Disease.

Hepatic and Cardiovascular Outcomes in Primary Biliary Cholangitis With Metabolic-Dysfunction Associated Steatotic Liver Disease.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: March 10, 2026

Reply to 'The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view'.

Reply to 'The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view'.

Journal: Nature reviews. Gastroenterology & hepatology

Published: February 19, 2026

Fracture risk under selective and non-selective PPAR agonists in primary biliary cholangitis.

Fracture risk under selective and non-selective PPAR agonists in primary biliary cholangitis.

Journal: Hepatology communications

Published: February 04, 2026

Low phospholipidassociated cholelithiasis syndrome

Low phospholipidassociated cholelithiasis syndrome

Journal: La Revue du praticien

Published: January 23, 2026

RIPK1 inhibition reduces biliary injury and fibrosis in primary sclerosing cholangitis.

RIPK1 inhibition reduces biliary injury and fibrosis in primary sclerosing cholangitis.

Journal: Science advances

Published: December 17, 2025

Meta-Analysis: PPAR Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis.

Meta-Analysis: PPAR Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis.

Journal: Alimentary pharmacology & therapeutics

Published: December 10, 2025

Prognostic performance of liver stiffness measurements in primary sclerosing cholangitis: the prospective FICUS cohort.

Prognostic performance of liver stiffness measurements in primary sclerosing cholangitis: the prospective FICUS cohort.

Journal: Gastroenterology

Published: November 13, 2025

Elafibranor in primary biliary cholangitis: two-year placebo-controlled outcomes and long-term open-label data from the ELATIVE® phase III trial.

Elafibranor in primary biliary cholangitis: two-year placebo-controlled outcomes and long-term open-label data from the ELATIVE® phase III trial.

Journal: Journal of hepatology

Published: November 12, 2025

Bezafibrate for primary biliary cholangitis: time to act on the evidence.

Bezafibrate for primary biliary cholangitis: time to act on the evidence.

Journal: Nature reviews. Gastroenterology & hepatology

Published: October 10, 2025

Graft and Patient Survival After Liver Transplantation for Primary Sclerosing Cholangitis: A French National Cohort Study.

Graft and Patient Survival After Liver Transplantation for Primary Sclerosing Cholangitis: A French National Cohort Study.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: June 16, 2025

ABCB4 disease-causing variants S242R, S346I, T437I and T1077M significantly impair its function and display differential sensitivity to potentiators.

ABCB4 disease-causing variants S242R, S346I, T437I and T1077M significantly impair its function and display differential sensitivity to potentiators.

Journal: Scientific reports

Published: May 13, 2025

Showing 1-12 of 131

Last Updated: 09/26/2026